U.S. markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5670-0.0020 (-0.35%)
At close: 04:00PM EST
0.5818 +0.01 (+2.61%)
After hours: 07:50PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.5690
Bid0.5636 x 800
Ask0.6100 x 1300
Day's Range0.5417 - 0.5994
52 Week Range0.2190 - 2.4200
Avg. Volume428,629
Market Cap10.919M
Beta (5Y Monthly)2.15
PE Ratio (TTM)N/A
EPS (TTM)-0.1600
Earnings DateNov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VIRI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virios Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/10/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Insider Monkey

    Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript

    Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript November 13, 2023 Virios Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.1. Operator: Good day, and welcome to the Virios Therapeutics, Inc. Third Quarter 2023 Earnings Update. At this time, all participants have been placed on a listen-only mode. Please be advised […]

  • Zacks Small Cap Research

    VIRI: Provides Overview of Phase 3 Program in Fibromyalgia

    By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Business Update Overview of Phase 3 Program for IMC-1 in Fibromyalgia Virios Therapeutics, Inc. (NASDAQ:VIRI) is developing IMC-1 (combination of famciclovir and celecoxib) as a therapy for fibromyalgia (FM). The company previously reported results from the Phase 2b FORTRESS trial in September 2022. Topline results showed that the

  • GlobeNewswire

    Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    - Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the third quarter ended September 30, 2023. Key Highlights and Upcoming Milestones Having secured FDA guidance on our plan to progress IM